title: Canine status epilepticus: a translational platform for human therapeutic trials.
abstract: Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.
authors.affiliation: Department of Experimental & Clinical Pharmacology, College of Pharmacy, University of Minnesota, 717 Delaware St SE,Minneapolis, MN 55414, USA. leppi001@umn.edu
authors.forename: Ilo E
authors.initials: IE
authors.lastname: Leppik
authors.forename: Edward N
authors.initials: EN
authors.lastname: Patterson
authors.forename: Lisa D
authors.initials: LD
authors.lastname: Coles
authors.forename: Elise M
authors.initials: EM
authors.lastname: Craft
authors.forename: James C
authors.initials: JC
authors.lastname: Cloyd
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D000077287:Levetiracetam; D010672:Phenytoin / Q000627:therapeutic use*; D010865:Pilot Projects; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015203:Reproducibility of Results; D013226:Status Epilepticus / Q000188:drug therapy*
chemical_list: D000927:Anticonvulsants; D000077287:Levetiracetam; D010672:Phenytoin; D010889:Piracetam